Search - tctmd.com

Displaying 1 - 20 of 226

Sort: Relevancy | Date

News Conference News ACC 2026

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Yael L. Maxwell

April 01, 2026

News Conference News ACC 2026

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

Michael O'Riordan

April 01, 2026

News Conference News ACC 2026

GoFreshRx, THRIVE Trials Show BP Benefits of ‘Food as Medicine’

L.A. McKeown

March 31, 2026

News Conference News ACC 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

Michael O'Riordan

March 30, 2026

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

News Conference News ACC 2026

Barbershop Effort Falls Short for Hypertension Prevention in Black Men

Todd Neale

March 29, 2026

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

News Conference News ACC 2026

KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension

Caitlin E. Cox

March 28, 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

L.A. McKeown

April 03, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

News Conference News ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Michael O'Riordan

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Presenter: Luke Laffin

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

Presentation ACC 2025

Four-Factor Prothrombin Complex Concentrate is Superior to Frozen Plasma in Bleeding Adult Cardiac Surgery Patients with Coagulopathy—Results from a Phase 3, Randomized, Active-Control Study

Presenter: Keyvan Karkouti

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Yael L. Maxwell

July 03, 2024

Advertisement

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

GoFreshRx, THRIVE Trials Show BP Benefits of ‘Food as Medicine’

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Barbershop Effort Falls Short for Hypertension Prevention in Black Men

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension

What’s Going to Be Hot at ACC 2026

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Four-Factor Prothrombin Complex Concentrate is Superior to Frozen Plasma in Bleeding Adult Cardiac Surgery Patients with Coagulopathy—Results from a Phase 3, Randomized, Active-Control Study

What’s Going to Be Hot at ACC 2025?

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content